drugset
Drugs / CD3-MUC1 Bispecific Antibody
last change Sep 2020 re-read 9 days ago

CD3-MUC1 Bispecific Antibody

also known as anti-CD3-MUC1 bispecific antibody

Other / unclassified targets MUC1

Developed for
breast cancer · colorectal cancer · digestive system carcinoma · gastric cancer · kidney cancer · liver cancer · lung cancer

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy7 trials
Phase 2 NCT03524261 Comparator May 2019 → Apr 2020 breast cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT03509298 Comparator Apr 2018 → May 2020 digestive system carcinoma Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT03540199 Comparator Apr 2018 → May 2020 kidney cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT03524274 Comparator Apr 2018 → May 2020 colorectal cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT03554395 Comparator Apr 2018 → May 2020 gastric cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as CD3-MUC1 Bispecific Antibody ClinicalTrials.gov intervention name — accepted as the source's own label NCT03524261 ↗
6

NCT03540199 ↗

NCT03554395 ↗

NCT03501056 ↗

NCT03524274 ↗

NCT03484962 ↗

NCT03509298 ↗
Known as anti-CD3-MUC1 bispecific antibody “This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer.” NCT03484962 ↗
Modality Other / unclassified “bispecific antibody of anti-CD3/MUC1” NCT03524261 ↗
Target MUC1 “bispecific antibody of anti-CD3/MUC1” NCT03501056 ↗